

**I. IN THE CLAIMS:**

This listing of claims below will replace all prior versions, and listings, of claims in the application:

**Listing of Claims:**

1-8. (Canceled)

9. (Currently Amended) An isolated monoclonal antibody against a ~~C-terminal peptide of GPC 3, wherein the C-terminal peptide of GPC 3 is a peptide consisting of amino acid residues 359-580~~ 375-580 of GPC 3 or a peptide consisting of amino acid residues 375-580 of GPC 3, as set forth in SEQ ID NO: 4, wherein the antibody has a cytotoxic activity against the cell line, HepG2 or HuH-7.

10-22. (Canceled)

23. (new) The antibody claimed in claim 9, wherein the cytotoxic activity is ADCC activity.

24. (new) The antibody claimed in claim 9, wherein the cytotoxic activity is CDC activity.

25. (new) The antibody claimed in claim 9 which is a recombinant antibody.

26. (new) The antibody claimed in claim 25, which is a humanized antibody.

27. (new) The humanized antibody claimed in claim 26, wherein the V region is derived from an antibody of a mammal except human and the C region is derived from a human antibody.

28. (new) The humanized antibody claimed in claim 27, wherein the C region of the H chain is selected from the group consisting of C $\gamma$ 1, C $\gamma$ 2, C $\gamma$ 3 and C $\gamma$ 4.

29. (new)      The humanized antibody claimed in claim 27, wherein the C region of the L chain is C $\kappa$  or C $\lambda$ .